Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line treatment of B-cell ALL; however, the treatment paradigm has been transformed over the past two decades with the advent of targeted agents such as tyrosine kinase inhibitors (Novartis’s Gleevec, Bristol Myers Squibb’s Sprycel, and Takeda’s Iclusig). Bispecific T-cell engagers (Amgen’s Blincyto), antibody-drug conjugates (Pfizer’s Besponsa), and CAR T-cell therapies (Novartis’s Kymriah, Gilead’s Tecartus) have further diversified treatment options for relapsed or refractory (R/R) disease. The emergence of these targeted therapies has improved the prognosis for patients and continues to expand the ALL treatment armamentarium.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 100 U.S. hematologist-oncologists.
Key drugs covered: Kymriah, Tecartus, Blincyto, Besponsa, Gleevec, Sprycel, Iclusig, and Marqibo.